Clinical Trials
276
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (220 trials with phase data)• Click on a phase to view related trials
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
- Conditions
- Radiotherapy, AdjuvantTACEImmune Checkpoint InhibitorNarrow MarginHepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Target Recruit Count
- 286
- Registration Number
- NCT07186621
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer
- Conditions
- Recurrent Cervical CancerMetastatic Cervical Cancer
- Interventions
- Biological: Iparomlimab and Tuvonralimab (QL1706) + Nab-Paclitaxelwith or without Bevacizumab
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Target Recruit Count
- 25
- Registration Number
- NCT07186868
The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy
- Conditions
- Esophageal Cancer
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Target Recruit Count
- 252
- Registration Number
- NCT07187154
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC
- Conditions
- Lung Cancer (NSCLC)
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Target Recruit Count
- 500
- Registration Number
- NCT07186855
- Locations
- 🇨🇳
Nationa Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijingn, China
Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease
- Conditions
- Rosai-Dorfman Disease
- Interventions
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Target Recruit Count
- 40
- Registration Number
- NCT07187167
- Locations
- 🇨🇳
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 55
- Next
News
Hypofractionated Radiotherapy Reduces Treatment Time and Toxicity While Maintaining Survival in Limited-Stage Small Cell Lung Cancer
A phase III trial of 530 patients across 16 Chinese hospitals demonstrated that three-week hypofractionated radiotherapy with concurrent chemotherapy provides comparable survival outcomes to standard six-week conventional radiotherapy for limited-stage small cell lung cancer.